Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series by de Moraes, Carlos Gustavo Vasconcelos et al.
TECHNICAL PERSPECTIVES
Intracameral bevacizumab and mitomycin C
Trabeculectomy for eyes with neovascular glaucoma:
a case series
Carlos Gustavo Vasconcelos de Moraes &
Antonio Carlos Facio Jr. & José Humberto Costa &
Roberto Freire Santiago Malta
Received: 14 July 2008 /Accepted: 10 March 2009 /Published online: 31 March 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract The purpose of this study was to describe the
surgical outcomes and safety of intracameral bevacizumab
during trabeculectomy in eyes with neovascular glaucoma.
Pilot study included four eyes (four patients) with refractory
neovascular glaucoma submitted to fornix-based trabecu-
lectomy with adjunctive use of bevacizumab in the anterior
chamber during the procedure. Patients were previously
treated with panretinal photocoagulation as standard thera-
py. Variables evaluated were intraocular pressure, bleb
appearance, iris neovascularization, intraoperative/postop-
erative complications, and visual outcomes. No intraoper-
ative complication was observed. The mean follow-up
period was 12.75 (range, 12–15 months). All eyes showed
significant intraocular pressure control postoperatively. Iris
neovascularization reduced significantly within 1 month
after surgery. Mild anterior chamber inflammation was
observed during follow-up in all eyes. No significant
postoperative complication was observed, and no patient
presented visual acuity deterioration. Intracameral bevaci-
zumab may be used as an adjunctive therapy during
trabeculectomy in eyes with neovascular glaucoma.
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Introduction
Neovascular glaucoma (NVG) is an optic disc neuropathy
caused by increased intraocular pressure (IOP), which
results from secondary angle closure due to the growth of
a neovascular membrane in the anterior chamber and
trabecular meshwork [1, 2]. Most cases of NVG are caused
by ischemic retinal diseases, such as diabetic retinopathy
and central or branch vein occlusions [2].
In such cases, standard treatment includes panretinal
photocoagulation (PRP) in addition to anti-glaucomatous
topical therapy [3–6]. Laser treatment aims to decrease the
stimulus of retinal neovascularization, which is attributed to
an increased concentration of vascular endothelial growth
factor (VEGF) in retinal ischemic tissue [7–9]. Adjunctive
therapy with topical medication delays the onset of
glaucomatous optic neuropathy, and most of these patients
will need glaucoma filtering procedures during follow-up
[1, 10–15].
There is currently no prospective, randomized trial
comparing success rates between trabeculectomy with
antimetabolites and tube implantation in eyes with NVG.
Non-comparative recent reports in the literature have shown
similar success rates between the two procedures [12–15].
Yalvac et al. reported 63% success rate at 1 year using
valved implants in eyes with NVG [15], whereas the
success rates of trabeculectomy with antimetabolites ranged
from 62% to 67% during the same follow-up time [13, 14].
The Tube Versus Trabeculectomy Study Group excluded
cases of iris neovascularization from their enrollment
criteria. The investigators based on the consensus that the
use of a glaucoma drainage implant (GDI) is the preferred
surgical approach with these types of refractory glaucomas
[16]. Nevertheless, most authors agree that GDIs are a
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e-mail: gustavonyee@gmail.combetter option in cases of NVG in a long-term follow-up [11,
15, 16]. Higher rates of failure following trabeculectomy
could be caused by the growth of a neovascular membrane
in the internal ostium of trabeculectomy, greater proximity
of the iris to corneal endothelium, and increased anterior
chamber inflammations in NVG eyes.
Bevacizumab (Avastin®, Genentech, Inc., USA) is a
monoclonal VEGF inhibitor that was first used in oph-
thalmology to treat subretinal neovascularization in eyes
with age-related macular disease [17–19]. Recently, intra-
vitreous injection of bevacizumab has been demonstrated to
be a safe and successful alternative to treat retinal neo-
vascularization in diabetic retinopathy and central or branch
vein occlusions [20–25]. Previous studies reported that
anterior chamber neovascularization may regress following
intravitreous injection of bevacizumab in eyes with NVG
[26–30], with [28, 29] or without [26, 30] adjunctive laser
treatment. Similar results were observed following intra-
cameral injections [31]. Since anterior chamber inflammation
and neovascular membranes may cause increased risk of
failure of filtration procedures, bevacizumab may be used as
an adjunctive therapy during surgical treatment of NVG.
The aim of this study was to describe the surgical
outcomes and safety of intracameral bevacizumab during
trabeculectomy in eyes with NVG.
Methods
This is a pilot study including four NVG patients who
underwent trabeculectomy with adjunctive use of bevaci-
zumab in the anterior chamber during the procedure.
Approval from the Institutional Review Board Ethics
Committee was obtained for the study. The study followed
the principles of the Declaration of Helsinki, and informed
consent was obtained from all subjects.
All patients presented with anterior chamber neo-
vascular membranes, closed angles during gonioscopy,
and high IOP (>21 mmHg). If the angle could not be
seen due to corneal edema, we based our judgment on
the depth of the peripheral anterior chamber (van
Herick’s test) and presence of iris neovascularization.
PRP was performed at the time of the initial presenta-
tion. In order to avoid complications associated with
excessive laser treatment in a single session, all eyes
were treated within a minimum of three (range, three to
five) consecutive visits, with a maximum of 300 shots
each visit using a spot size of 250 µm with delivery
energy of 200–500 J. The aim was to allow a 360°
scatter PRP with a range of 900–1500 shots by the last
visit. All eyes were on antiglaucoma medication by the
time of the procedure.
Trabeculectomy was performed by two glaucoma spe-
cialists (ACFJ and JHC). Briefly, trabeculectomy was
performed as follows: A fornix-based flap of conjunctiva
and Tenon’s capsule was created. After haemostasis of the
episcleral blood vessels with wet-field cautery, a one-half
thickness rectangular (4.0×2.0 mm) scleral flap (1.5 mm
from the limbus) was outlined and dissected anteriorly
without entry into the anterior chamber. Three surgical
sponges measuring 2.0×2.0 mm were soaked in a solution
of 0.5 mg/ml mitomycin C (MMC). The sponges were
placed over the dissected bed; a superficial scleral flap and
the conjunctiva-tenon layer were then draped over the
MMC-soaked sponges so that only those ocular tissues in
contact with the sponges were directly exposed to MMC.
After 3 min, the sponges were removed, and MMC was
irrigated thoroughly with 20 ml balanced salt solution. A
deep trabecular block was removed, and a peripheral
iridectomy was performed.
The scleral flap was closed with three interrupted 10-0
nylon sutures. The conjuntivo-tenon flap was closed in the
limbus using two interrupted 10-0 nylon sutures (one in each
side of the flap, involving the corneal limbus—tenon—
conjunctiva). After the closure, the conjunctiva was shown to
be watertight.
Then, 1.25 mg of bevacizumab [32] (0.05 ml of 25 mg/ml
solution) was injected in the anterior chamber through the
Table 1 Overview of surgical outcomes
Patient Diagnosis Preoperative
number of
medications
Postoperative
number of
medications
Preoperative
IOP (mmHg)
Last visit
IOP
(mmHg)
Follow-up
time
(months)
Complications
1 PDR 4 0 54 14 12 –
2 PDR
+BVO
4 0 70 10 15 Flat anterior chamber,
serous choroidal
detachment
3 PDR 3 0 58 12 12 –
4 PDR 4 0 44 10 12 Transient IOP elevation,
hyphema
PDR proliferative diabetic retinopathy, BVO branch vein occlusion
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preparation and atropine 1% was instilled in the conjunctival
sac, and a patch and shield were applied on the eye.
The postoperative medical regimen initially included
1.0% prednisolone eye drops administered every 2 h and
then tapered over a period of 6 weeks, depending on the
degree of inflammation. Atropine 1% was dropped three
times a day for the first 4 weeks after surgery. Topical
antibiotic (moxyfloxacin, 0.5%) was also administered four
times daily during 2 weeks after surgery.
All patients were seen on the first postoperative day and
then on the third, fifth, seventh, tenth, and 15th day and
then on the first, third, sixth, ninth, and 12th months
thereafter. At each visit, complete ophthalmic evluation
included best corrected visual acuity (BCVA), corneal
appearance, anterior chamber depth, IOP measurements
using Goldman tonometry, bleb appearance, and fundus
examination.
Results
All patients presented with proliferative diabetic retinopa-
thy, and one patient had a superimposed branch vein
occlusion. None of the surgeries presented any intraoper-
ative complication. The summary of each case is presented
below (overview in Table 1).
Patient 1
A 65-year-old white woman with history of diabetic
retinopathy presented with proliferative disease in the left
eye. Preoperative IOP was 54 mmHg using beta-blocker,
alpha-agonist, and dorzolamide eye drops and oral acet-
azolamide 250 mg four times daily. Peripheral anterior
synechiae (PAS) were present in 180° extension of the
angle. BCVA was count fingers at 2 m (Fig. 1).
On the first postoperative day, the IOP was 12 mmHg
(initial reduction, 77%), with a diffuse elevated bleb, mild
corneal edema, and little anterior chamber reaction (Fig. 2).
No change in fundus appearance was observed during
indirect ophthalmoscopy.
By the end of the first week, the IOP was 10 mmHg.
Suture lysis (one suture) was performed using argon laser
on the 15th day visit due to transient mild IOP elevation. At
the last follow-up visit (12 months), she presented with a
visual acuity of 20/200, likely due to decreased corneal
edema, and the IOP was 14 mmHg (final IOP reduction,
74%). There was no sign of iris neovascularization by the
last visit. The bleb conjunctiva looked more avascular than
preoperatively and also less hyperemic than the surround-
ing non-operated conjunctiva.
Fig. 1 Preoperative biomicroscopic examination. Note the extensive
iris neovascularization, corneal edema, and mydriais (black arrow)
Fig. 2 First day post-surgery. Note the significant reduction of iris
neovascularization
Fig. 3 One week after surgery. The bleb is diffuse, conjuctival vessels
have small caliber, and anterior chamber inflammation is mild
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A 37-year-old black man with previous diagnosis of
diabetic retinopathy presented with branch vein occlusion
in the right eye. Preoperative IOP was 70 mmHg on
maximal tolerated therapy. BCVA was hand-motion. The
angle was closed in all four sectors during gonioscopy.
In the first postoperative day, the IOP was 14 mmHg
(initial reduction, 80%). On the fifth day, he presented with
flat anterior chamber (iridocorneal contact), with spontane-
ous resolution on the seventh day. An elevated non-vascular
bleb was observed during all further follow-up visits.
Fifteen months later, the IOP was 10 mmHg, and the
BCVAwas count fingers at 1 m (final IOP reduction, 86%).
There was significant decrease in iris neovascularization,
and the bleb showed little hyperemia.
Patient 3
A 56-year-old white woman was diagnosed with prolifer-
ative diabetic retinopathy in the right eye. Preoperative IOP
was 58 mmHg on three antiglaucoma medications (beta
blocker, alpha-agonist, and oral acetazolamide 250 mg four
times daily). BCVA was 20/80 preoperatively. The four
sectors of the angle were closed during gonioscopy.
The intraocular pressure (IOP) was 10 mmHg on the first
postoperative day (initial reduction, 83%). By the end of
the first week, the IOP was 12 mmHg, and no sign of iris
neovascularization was present (Fig. 3). By the last follow-
up visit (12 months), the IOP was 12 mmHg (final IOP
reduction, 80%) and visual acuity remained 20/80. The iris
and bleb remained avascular until the final visit.
Patient 4
A 45-year-old white woman presented with proliferative
diabetic retinopathy, and the IOP was 44 mmHg on
maximal tolerated medication. BCVA was count-fingers at
2 m, and anterior segment biomichoscopy showed intense
iris neovascularization with flat anterior chamber. On the
first postoperative day, the IOP was 8 mmHg (initial
reduction, 82%) and showed continuous elevation until
the 30th day visit when it reached 20 mmHg. Suture lysis
was performed associated with subconjunctival injection of
0.5 mg of 5-fluorouracil. One month later, the IOP was
10 mmHg and remained the same until the last visit
(12 months; final IOP reduction, 77%). BCVA improved to
20/100. Iris neovascularization was not evident during
biomicrospic evaluation, and the bleb was avascular and
less hyperemic than the surrounding conjunctiva (Fig. 4).
Fig. 4 One month after surgery. Note that the bleb is diffuse and
avascular
Fig. 5 Intraocular pressure pro-
file following trabeculectomy
with bevacizumab
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Biomicroscopic examination revealed complete regression
of iris rubeosis by the last follow-up visit in all patients.
Subjective evaluation of conjunctival vessels showed an
improvement of ocular surface hyperemia following the
procedure. Anterior chamber inflammation was considered
mild (aqueous humor flare during slit-lamp examination) in
all eyes within 1 week follow-up. By the second week after
surgery, none of the operated eyes showed any subjective
signs of anterior segment inflammation as determined by
biomicroscopic evaluation. Patient 4 presented with
hyphema (2 mm) during the first week, with further
spontaneous resolution by the end of the second week.
Mild serous choroidal detachment was seen in patient 3
with no further clinical consequences and resolved sponta-
neously (Fig. 5).
Discussion
In this study, a selected group of patients presented
significant IOP reduction following trabeculectomy with
adjunctive use of intracameral bevacizumab after an
average follow-up period of 12.75 months. No significant
intraoperative or late onset complication was reported.
Secondary glaucomas and eyes with previous intraocular
surgery are at increased risk of failure following glaucom-
atous filtering procedures [33–35]. NVG may affect the
properties of the conjunctiva and anterior chamber, result-
ing in increased risk of failure in eyes submitted to
trabeculectomy. Glaucoma drainage implants are thus
indicated as a further procedure in patients who did not
present satisfactory IOP control with topical medication.
Yet, GDIs are more expensive than standard trabeculectomy
and may result in increased risk of short- and long-term
complications (e.g., extrusion, diplopia, and endophthalmi-
tis) [11]. Eyes with NVG were excluded from the Tube
Versus Trabeculectomy Study, which may not allow us to
make any definite assumptions whether GDIs represent an
increased risk of future complications in NVG eyes [16].
Alternatively, adjunctive use of bevacizumab during trabe-
culectomy could be a safe and efficient procedure in NVG,
as suggested in our study.
Intravitreal injection of bevacizumab has already been
studied in NVG [28–30]. Geith and colleagues described a
case series of six NVG patients who underwent PRP
followed by intravitreal injection of bevacizumab [28].
The authors reported that eyes without synechiae showed
satisfactory IOP control with topical eye drops alone, while
those with PAS at the time of presentation needed
subsequent glaucoma surgery. They suggested that intra-
vitreal bevacizumab may be a valuable addition in the
treatment of NVG by hastening the resolution of anterior
segment neovascularization, improving the results of
glaucoma surgeries, and appearing to give long-term
control when used in combination with PRP. The procedure
did not result in any relevant side effects in their study and
showed a significant IOP decrease with mild inflammation.
Kahook et al. have reported a case of bleb needling
revision using bevacizumab, demonstrating that the bleb
was noted to be more diffuse with a decrease in surface
neovascularization [36]. They suggested that the drug may
be an effective medication for rescuing failing filtering
blebs that exhibit neovascularization. In our study, it was
noted that the number and caliber of vessels over the bleb
significantly decreased after the surgery, unlikely what
would be expected in cases of NVG. We believe that after
the injection of bevacizumab, part of the drug diffuses
through the sub-Tenon space resulting in decreased stimu-
lus for neovascularization and bleb failure. A longer period
of follow-up time is necessary to confirm this hypothesis.
Iliev et al. evaluated glaucoma control in eyes with NVG
following retinal vein occlusion after intravitreal injection
of bevacizumab.[37] The authors observed rapid regression
of iris and angle neovascularization and suggested further
studies using VEGF inhibitors as adjunct therapy in the
management of NVG. Recent reports described similar
results and suggested new perspectives in the treatment of
this type of refractory glaucoma [38, 39]. Our study
confirmed those findings and also addressed one of its
potential uses in glaucoma management.
One limitation of our study was the lack of a control
group. Nevertheless, trabeculectomy with antimetabolites
and bevacizumab should be compared with a control group
without bevacizumab. However, since it is well known that
trabeculectomy (even with adjunctive MMC) has high risk
of failure in NVG, a comparative study using a group
without bevacizumab would face ethical issues. Alterna-
tively, a comparative study with tube implants would be
biased for using a completely different surgical modality.
Due to the lack of a control group, we cannot speculate
whether the observed results are due to the intracameral use
of bevacizumab or the PRP combined with the use of MMC
intraoperatively. Based on our experience and on the
available literature, the success rates of trabeculectomy
even with adjunctive use of antimetabolites are very low
(approximately 58% in 2 years) [13]. It is possible that the
transitory anti-VEGF effect of the drug might have
contributed to success by reducing inflammation and
inhibiting excessive bleb vascularization, which are the
main causes of failure in these eyes. Despite the growing
use of monoclonal VEGF inhibitors in retinal disease, it is
consensus that PRP should always be considered as first
choice treatment in neovascular retinal diseases, as it has
been validated by the major clinical trials in the area [3, 4].
44 j ocul biol dis inform (2009) 2:40–46We also used a high concentration of MMC (0.5 mg/ml) in
these eyes, which may have also contributed to the
avascular appearance of the bleb during follow-up.
In summary, intracameralinjectionofbevacizumab during
trabeculectomy in this sample of patients with NVG resulted
in satisfactory IOP control during a mid-term follow-up
period with minor complications. Further prospective case–
control studies are necessary to confirm these results.
Financial disclosure The authors have no financial interest in this
article
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Sivack-Callcott JA, O’Day DM, Gass DM, et al. Evidence based
recommendations for the diagnosis and treatment of neovascular
glaucoma. Ophthalmology. 2001;108:1767–76.
2. Allingham RA, Damji KF, Freedman S, et al. Glaucomas
associated with disorders of the retina, vitreous and choroids. In:
Shields’ Textbook of Glaucoma, 5th edn. Philadelphia: Lippin-
cott, Williams & Wilkins; 2005.
3. Central Vein Occlusion Study Group. Natural history and clinical
management of central retinal vein occlusion. Arch Ophthalmol.
1997;115:486–91.
4. Aylward GW, Pearson RV, Jagger JD, Hamilton AM. Extensive
argon laser photocoagulation in the treatment of proliferative
diabetic retinopathy. Br J Ophthalmol. 1989;73:197–201.
5. Doft BH, Blankenship GW. Single vs multiple treatment sessions
of argon laser panretinal photocoagulation for proliferative
diabetic retinopathy. Ophthalmology. 1982;89:772–9.
6. Kaufman SC, Ferris FLIII, Seigel DG, et al. Factors associated
with visual outcome after photocoagulation for diabetic retinop-
athy: diabetic retinopathy study report 13. Invest Ophthalmol Vis
Sci. 1989;30:23–8.
7. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular
endothelial growth factor levels in the vitreous of eyes with
proliferative diabetic retinopathy. Am J Ophthalmol. 1994;
118:445–50.
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial
growth factor in ocular fluid of patients with diabetic retinop-
athy and other retinal disorders. N Engl J Med. 1994;331:1480–
7.
9. Pe’er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of
vascular endothelial growth factor by retinal cells is a common
factor in neovascularizing ocular diseases. Lab Invest.
1995;72:638–45.
10. Sidoti PA, Dunphy TR, Baerveldt G, et al. Experience with the
Baerveldt glaucoma implant in treating neovascular glaucoma.
Ophthalmology. 1995;102:1107–18.
11. Hong CH, Arosemena A, Zurakowski D, et al. Glaucoma drainage
devices: a systematic literature review and current controversies.
Surv Ophthalmol. 2005;50:48–60.
12. Sivak-Callcott JA, O’Day DM, Gass JD, et al. Evidence-based
recommendations for the diagnosis and treatment of neovascular
glaucoma. Ophthalmology. 2001;108:1767–76.
13. Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with
mitomycin C for neovascular glaucoma: prognostic factors for
surgical failure. Am J Ophthalmol. 2009, (in press).
14. Kiuchi Y, Sugimoto R, Nakae K, et al. Trabeculectomy with
mitomycin C for treatment of neovascular glaucoma in diabetic
patients. Ophthalmologica. 2006;220:383–8.
15. Yalvac IS, Eksioglu U, Satana B, et al. Long-term results of
Ahmed glaucoma valve and Molteno implant in neovascular
glaucoma. Eye. 2007;21:65–70.
16. Tube Versus Trabeculectomy Study Group. The tube versus
trabeculectomy study: design and baseline characteristics of study
patients. Am J Ophthalmol. 2005;140:275–87.
17. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal
bevacizumab (Avastin) for neovascular age-related macular
degeneration. Ophthalmology. 2006;113:363–5.
18. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of
experimental choroidal neovascularization with intravitreal anti-
vascular endothelial growth factor antibody fragment. Arch
Ophthalmol. 2002;120:338–46.
19. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence
tomography findings after an intravitreal injection of bevacizumab
(Avastin) for neovascular age-related macular degeneration.
Ophthalmic Surg Lasers Imaging. 2005;36:331–5.
20. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab
(Avastin) for proliferative diabetic retinopathy: 6-months follow-
up. Eye. 2007;23:117–23.
21. Ishikawa K, Honda S, Tsukahara Y, et al. Preferable use of
intravitreal bevacizumab as a pretreatment of vitrectomy for
severe proliferative diabetic retinopathy. Eye. 2007;23:108–
11.
22. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular
diseases. Ann Pharmacother. 2007;41:614–25.
23. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab
(Avastin) for central and hemicentral retinal vein occlusions:
IBeVO study. Retina. 2007;27:141–9.
24. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizu-
mab (Avastin) in the treatment of proliferative diabetic retinopa-
thy. Ophthalmology. 2006;113:1695.
25. Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, et
al. Bevacizumab for treatment of macular edema secondary to
retinal vein occlusion. Ophthalmologe. 2006;103:471–5.
26. Bock F, Konig Y, Dietrich T, et al. Inhibition of angiogenesis in
the anterior chamber of the eye. Ophthalmologe. 2007;104:336–
44.
27. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber
inflammatory activity in eyes treated with intravitreal bevacizu-
mab. Retina. 2006;26:877–81.
28. Gheith ME, Siam GA, De Barros DS, et al. Role of intravitreal
bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther.
2007;23:487–91.
29. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the
treatment of neovascular glaucoma. Clin Exp Ophthalmol.
2007;35:494–6.
30. Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and
iris neovascularization after a single intravitreal bevacizumab
injection in a patient with central retinal vein occlusion and
neovascular glaucoma. Int Ophthalmol. 2007;28:59–61.
31. Grisanti S, Biester S, Peters S, et al. Tuebingen Bevacizumab
Study Group. Intracameral bevacizumab for iris rubeosis. Am J
Ophthalmol. 2006;142:158–60.
32. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizu-
mab for filtering surgery. Ophthalmic Res. 2007;39:121–2.
33. Lavin MJ, Wormald RP, Migdal CS, et al. The influence of prior
therapy on the success of trabeculectomy. Arch Ophthalmol.
1990;108:1543–8.
j ocul biol dis inform (2009) 2:40–46 4534. Bayer AU, Erb C, Ferrari F, et al. The Tubingen Glaucoma
Study. Glaucoma filtering surgery—a retrospective long-term
follow-up of 254 eyes with glaucoma. Ger J Ophthalmol.
1995;4:289–93.
35. Jacobi PC, Dietlein TS, Krieglestein GK. Primary trabeculectomy
in young adults: long-term clinical results and factors
influencing the outcome. Ophthalmic Surg Lasers. 1999;30:637–
46.
36. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of
encapsulated filtering bleb with bevacizumab. Ophthalmic Surg
Lasers Imaging. 2006;37:148–50.
37. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal
bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Am J Ophthalmol. 2006;142:1054–6.
38. Miki A, Oshima Y, Otori Y, et al. Efficacy of intravitreal
bevacizumab as adjunctive treatment with pars plana vitrectomy,
endolaser photocoagulation, and trabeculectomy for neovascular
glaucoma. Br J Ophthalmol. 2008;92:1431–3.
39. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal
bevacizumab to treat iris neovascularization and neovascular
glaucoma secondary to ischemic retinal diseases in 41 consecutive
cases. Ophthalmology. 2008;115:1571–80.
46 j ocul biol dis inform (2009) 2:40–46